Fig. 3
From: Generation of a new transgenic mouse model for assessment of tau gene silencing therapies
![Fig. 3](http://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs13195-016-0202-1/MediaObjects/13195_2016_202_Fig3_HTML.gif)
Ex vivo analysis of Luciferase and tau levels. The forebrains of bigenic and single transgenic mice (n = 3 each genotype) were homogenized in PBS (10 % weight/volume). a Two different amounts of each homogenate were assayed for luciferase activity as described in “Methods.” Only the bigenic tTA/TUL mice produced high levels of luciferase activity. Bigenic tTA/TUL mice fed chow containing Dox produced 90 % less luciferase activity. The error bar estimates standard deviation. b Immunoblot of brain homogenates for tau with a monoclonal antibody that specifically reacts with human tau (clone Tau-13). The brain homogenates of three different tTA/TUL mice (no Dox) and three different tTA/TUL mice fed Dox chow for 7 days, along with non-transgenic brain homogenates and mice transgenic for only the TUL responder transgene were analyzed. Each lane contains 50 μg of total protein